{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:22:26Z","timestamp":1791829346714,"version":"4.3.4"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ctrv.2020.102011","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T01:01:30Z","timestamp":1584493290000},"page":"102011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B\/C, HIV): A review of the available evidence"],"prefix":"10.1016","volume":"86","author":[{"given":"G.","family":"Tapia Rico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.F.","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102011_b0005","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s12272-016-0850-5","article-title":"Immune checkpoint inhibitors for cancer treatment","volume":"39","author":"Park","year":"2016","journal-title":"Arch Pharmacal Res"},{"key":"10.1016\/j.ctrv.2020.102011_b0010","doi-asserted-by":"crossref","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. 2018;8.","DOI":"10.3389\/fonc.2018.00086"},{"key":"10.1016\/j.ctrv.2020.102011_b0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102011_b0020","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/j.jtho.2016.08.106","article-title":"P2.35: Nivolumab vs docetaxel in advanced NSCLC: CheckMate 017\/057 2-Y update and exploratory cytokine profile analysis: track: immunotherapy","volume":"11","author":"Borghaei","year":"2016","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0025","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.ctrv.2020.102011_b0030","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102011_b0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0040","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102011_b0045","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.ctrv.2020.102011_b0050","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102011_b0065","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site - when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102011_b0070","doi-asserted-by":"crossref","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of clinical oncology and friends of cancer research joint research statement. 2017;35:3737\u201344.","DOI":"10.1200\/JCO.2017.73.7916"},{"key":"10.1016\/j.ctrv.2020.102011_b0075","doi-asserted-by":"crossref","unstructured":"Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, Bruinooge S, et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology\u2013Friends of Cancer Research HIV Working Group. 2017;35:3774\u201380.","DOI":"10.1200\/JCO.2017.73.7338"},{"key":"10.1016\/j.ctrv.2020.102011_b0080","unstructured":"World Health Organization. HIV\/AIDS. 2019, November 15. Retrieved from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"10.1016\/j.ctrv.2020.102011_b0085","unstructured":"World Health Organization. Hepatitis B. 2019, July 2018. Retrieved from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"10.1016\/j.ctrv.2020.102011_b0090","unstructured":"World Health Organization. Hepatitis C. 2019, July 9. Retrieved from https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"10.1016\/j.ctrv.2020.102011_b0095","doi-asserted-by":"crossref","unstructured":"Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. 2017;35:3745\u201352.","DOI":"10.1200\/JCO.2017.73.4186"},{"key":"10.1016\/j.ctrv.2020.102011_b0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","article-title":"Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices","volume":"5","author":"Ramsey","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4254\/wjh.v8.i8.385","article-title":"Management of hepatitis B reactivation in immunosuppressed patients: an update on current recommendations","volume":"8","author":"Bessone","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ctrv.2020.102011_b0110","doi-asserted-by":"crossref","first-page":"e35810-e","DOI":"10.5812\/hepatmon.35810","article-title":"Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: A comprehensive review-screened","volume":"16","author":"Tavakolpour","year":"2016","journal-title":"Hepat Mon"},{"key":"10.1016\/j.ctrv.2020.102011_b0115","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2020.102011_b0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.critrevonc.2015.10.017","article-title":"Hepatitis B and cancer: a practical guide for the oncologist","volume":"98","author":"Bozza","year":"2016","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.ctrv.2020.102011_b0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.ctrv.2020.102011_b0130","doi-asserted-by":"crossref","unstructured":"Watanabe T, Bertoletti A, Tanoto TA. PD-1\/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. 2010;17:453\u20138.","DOI":"10.1111\/j.1365-2893.2010.01313.x"},{"key":"10.1016\/j.ctrv.2020.102011_b0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ctrv.2020.102011_b0140","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2020.102011_b0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ctrv.2020.102011_b0150","doi-asserted-by":"crossref","first-page":"33-","DOI":"10.1186\/s40425-014-0033-1","article-title":"Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series","volume":"2","author":"Ravi","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102011_b0155","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and management of hepatitis in patients on checkpoint blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2020.102011_b0160","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. 2018;36:1714\u201368."},{"key":"10.1016\/j.ctrv.2020.102011_b0165","doi-asserted-by":"crossref","unstructured":"Ragunathan K, Dadana S, Huang C-H. Hepatitis B reactivation after administration of pembrolizumab (KEYTRUDA): a unique case report: 2145. 2017;112:S1187\u2013S8.","DOI":"10.14309\/00000434-201710001-02146"},{"key":"10.1016\/j.ctrv.2020.102011_b0170","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ctrv.2020.102011_b0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ctrv.2020.102011_b0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/gast.2002.31602","article-title":"Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection","volume":"122","author":"Biancone","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2020.102011_b0185","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2020.102011_b0190","doi-asserted-by":"crossref","first-page":"461879-","DOI":"10.1155\/2013\/461879","article-title":"Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease","volume":"2013","author":"Miyake","year":"2013","journal-title":"Case Reports Hepatol"},{"key":"10.1016\/j.ctrv.2020.102011_b0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cld.728","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"12","author":"Terrault","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.ctrv.2020.102011_b0200","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1093\/annonc\/mdx502","article-title":"HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma","volume":"28","author":"Koksal","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0205","first-page":"5985131-","article-title":"A rare case of pembrolizumab-induced reactivation of hepatitis B","volume":"2018","author":"Pandey","year":"2018","journal-title":"Case Rep Oncol Med."},{"key":"10.1016\/j.ctrv.2020.102011_b0210","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"AIDS (London, England)."},{"key":"10.1016\/j.ctrv.2020.102011_b0215","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"104","key":"10.1016\/j.ctrv.2020.102011_b0220","first-page":"137","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"2018","author":"Tio","year":"1990","journal-title":"Eur J Cancer (Oxford, England"},{"key":"10.1016\/j.ctrv.2020.102011_b0225","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CMR.0000000000000256","article-title":"Safety of immune checkpoint inhibitors in Chinese patients with melanoma","volume":"26","author":"Wen","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2020.102011_b0230","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000434","article-title":"Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series","volume":"28","author":"Kothapalli","year":"2018","journal-title":"Melanoma Res"},{"issue":"1273\u201383","key":"10.1016\/j.ctrv.2020.102011_b0235","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2020.102011_b0240","doi-asserted-by":"crossref","first-page":"e194757-e","DOI":"10.1001\/jamanetworkopen.2019.4757","article-title":"Concerns about direct-acting antiviral agents for hepatitis C\u2014cause for reassurance","volume":"2","author":"Beste","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.ctrv.2020.102011_b0245","article-title":"Drug-drug interactions potential of direct-acting antivirals for the treatment of chronic hepatitis C virus infection","volume":"105571","author":"N\u00e9ant","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ctrv.2020.102011_b0250","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1200\/JOP.2013.001215","article-title":"Hepatitis C virus screening in patients with cancer receiving chemotherapy","volume":"10","author":"Hwang","year":"2014","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ctrv.2020.102011_b0255","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7326\/L17-0476","article-title":"Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus","volume":"167","author":"Mahale","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2020.102011_b0260","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.ctrv.2020.102011_b0265","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2020.102011_b0270","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/imj.14131","article-title":"Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir)","volume":"48","author":"Menon","year":"2018","journal-title":"Int Med J"},{"key":"10.1016\/j.ctrv.2020.102011_b0275","first-page":"737389-","article-title":"PD-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.ctrv.2020.102011_b0280","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JOP.2016.019224","article-title":"Antitumor and anti-hepatitis C viral response after administration of the anti-programmed death 1 antibody pembrolizumab","volume":"13","author":"Jang","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ctrv.2020.102011_b0285","first-page":"44-","article-title":"PD-1 blockade in advanced urothelial carcinoma with chronic hepatitis C: case report","volume":"12","author":"Krieger","year":"2016","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0290","doi-asserted-by":"crossref","unstructured":"Minter S, Willner I, Shirai K. Ipilimumab-induced hepatitis C viral suppression. 2013;31:e307\u2013e8.","DOI":"10.1200\/JCO.2012.46.5831"},{"key":"10.1016\/j.ctrv.2020.102011_b0295","doi-asserted-by":"crossref","first-page":"e97482-e","DOI":"10.1371\/journal.pone.0097482","article-title":"Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2020.102011_b0300","doi-asserted-by":"crossref","unstructured":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. 2015;373:795\u2013807.","DOI":"10.1056\/NEJMoa1506816"},{"key":"10.1016\/j.ctrv.2020.102011_b0305","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.ctrv.2020.102011_b0310","doi-asserted-by":"crossref","unstructured":"Puronen CE, Ford ES, Uldrick TS. Immunotherapy in people with HIV and cancer. 2019;10.","DOI":"10.3389\/fimmu.2019.02060"},{"key":"10.1016\/j.ctrv.2020.102011_b0315","doi-asserted-by":"crossref","unstructured":"Burke MM, Kluger HM, Golden M, Heller KN, Hoos A, Sznol M. Case Report: Response to ipilimumab in a patient with HIV with metastatic melanoma. 2011;29:e792\u2013e4.","DOI":"10.1200\/JCO.2011.36.9199"},{"key":"10.1016\/j.ctrv.2020.102011_b0320","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS (London, England)."},{"key":"10.1016\/j.ctrv.2020.102011_b0325","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0330","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.ctrv.2020.102011_b0335","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.21037\/jtd.2017.05.32","article-title":"Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer","volume":"9","author":"McCullar","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ctrv.2020.102011_b0340","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/annonc\/mdx321","article-title":"Nivolumab in HIV-related non-small-cell lung cancer","volume":"28","author":"Hentrich","year":"2017","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0345","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-017-0252-3","article-title":"Nivolumab as salvage treatment in a patient with HIV-related relapsed\/refractory Hodgkin lymphoma and liver failure with encephalopathy","volume":"5","author":"Sandoval-Sus","year":"2017","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ctrv.2020.102011_b0350","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/jdv.14450","article-title":"Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab","volume":"32","author":"Tomsitz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"10.1016\/j.ctrv.2020.102011_b0355","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000490636","article-title":"Favorable response to treatment with avelumab in an HIV-positive patient with advanced merkel cell carcinoma previously refractory to chemotherapy","volume":"11","author":"Al Homsi","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0360","doi-asserted-by":"crossref","first-page":"66-","DOI":"10.1186\/s40425-018-0379-x","article-title":"Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection","volume":"6","author":"Husnain","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102011_b0365","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdy259","article-title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","volume":"29","author":"Scully","year":"2018","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0370","first-page":"946392-","article-title":"A Patient with HIV treated with ipilimumab and stereotactic radiosurgery for melanoma metastases to the brain","volume":"2013","author":"Ruzevick","year":"2013","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.ctrv.2020.102011_b0375","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0380","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Cao M, Moran T, Dalmau J, Garcia-Corbacho J, Bernab\u00e9 R, Juan O, et al. Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected. 2019;37:2501.","DOI":"10.1200\/JCO.2019.37.15_suppl.2501"},{"key":"10.1016\/j.ctrv.2020.102011_b0385","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0390","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS (London, England)"},{"issue":"41","key":"10.1016\/j.ctrv.2020.102011_b0395","first-page":"379","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"2018","author":"Chang","year":"1997","journal-title":"J Immunother (Hagerstown, Md)"},{"key":"10.1016\/j.ctrv.2020.102011_b0400","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdx817","article-title":"PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?","volume":"29","author":"Lavol\u00e9","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0405","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12094-018-1981-6","article-title":"Cancer immunotherapy of patients with HIV infection","volume":"21","author":"Gonzalez-Cao","year":"2019","journal-title":"Clin Transl Oncol: Off Publ Feder Spanish Oncol Soc Natl Cancer Inst Mexico"},{"key":"10.1016\/j.ctrv.2020.102011_b0410","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0415","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2020.102011_b0420","unstructured":"Samri A LA, Even S, Lambert-Niclot S, Le Garff G, Cadranel J. Immunovirological evolution in HIV-infected patients treated with anti-PD-1 therapy. In: International AIDS society conference. Paris, France."},{"key":"10.1016\/j.ctrv.2020.102011_b0425","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1093\/annonc\/mdx538","article-title":"Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients","volume":"28","author":"Heppt","year":"2017","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0430","doi-asserted-by":"crossref","unstructured":"Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade; 2018.","DOI":"10.1158\/2326-6066.CIR-18-0121"},{"key":"10.1016\/j.ctrv.2020.102011_b0435","doi-asserted-by":"crossref","unstructured":"Park S, Sacco AG, Cohen EEW, Daniels GA. Safety and efficacy of checkpoint inhibition (CI) in cancer patients (pts) with concurrent human immunodeficiency virus (HIV) infection. 2018;36:136.","DOI":"10.1200\/JCO.2018.36.5_suppl.136"},{"key":"10.1016\/j.ctrv.2020.102011_b0440","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0445","doi-asserted-by":"crossref","first-page":"xi33-xi4","DOI":"10.1093\/annonc\/mdz451.001","article-title":"Nivolumab plus low-dose IPILIMUMAB as first-line treatment of advanced NSCLC: overall survival analysis of checkmate 817","volume":"30","author":"Barlesi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2020.102011_b0450","unstructured":"The U.S Food and Drug Administration (FDA). Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections. 2019, 3 March."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:22:41Z","timestamp":1759656161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":90,"alternative-id":["S0305737220300499"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737636901.793573274","asserted-by":"object"}]},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B\/C, HIV): A review of the available evidence","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102011"}}